SCHEMBL104201

SCHEMBL104201

Cc1ccc(OC(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 1/20 0.54
KMT2A Q03164 4/20 0.53
MAPT P10636 3/20 0.53
ALDH1A1 P00352 3/20 0.53
NLRP1 Q9C000 1/20 0.53
ACHE P22303 2/20 0.50
PARP10 Q53GL7 1/20 0.50
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 1/20 0.47
CNR2 P34972 1/20 0.46
SCN5A Q14524 1/20 0.46
SCN2A Q99250 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
GLA P06280 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.43
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
TEAD4 Q15561 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8364605 0.93 KMT2A (0.49) ALDH1A3KMT2AMAPTALDH1A1NLRP1
SCHEMBL125543 0.88 ALDH1A3 (0.64) ALDH1A3KMT2AALDH1A1PARP10POLB
SCHEMBL16406583 0.87 MAPT (0.45) ALDH1A3KMT2AMAPTALDH1A1NLRP1
SCHEMBL10047613 0.87 MAPT (0.45) ALDH1A3KMT2AMAPTALDH1A1NLRP1
SCHEMBL1162019 0.83 ACHE (0.50) ALDH1A3KMT2AMAPTALDH1A1NLRP1
SCHEMBL18997928 0.83 KMT2A (0.63) KMT2AMAPTALDH1A1NLRP1PARP10
SCHEMBL21558858 0.83 MAPT (0.46) ALDH1A3KMT2AMAPTALDH1A1NLRP1
Hydrogen Peroxide SCHEMBL28902806 0.82 KMT2A (0.70) ALDH1A3KMT2AALDH1A1PARP10POLB
SCHEMBL23128645 0.82 MAOB (0.56) KMT2AMAPTALDH1A1NLRP1PARP10
SCHEMBL9102528 0.82 KMT2A (0.85) KMT2AMAPTALDH1A1NLRP1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114854489-B Chamomile essential oil and preparation method and application thereof 北京市农林科学院 2024-03-22 CN claimed
EP-4277591-A1 ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR Momentive Performance Materials GmbH (DE) 2023-11-22 EP claimed
CN-114854489-A Essential oil of Mao Huaju, preparation method and application thereof 北京市农林科学院 2022-08-05 CN claimed
WO-2022152742-A1 ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR MOMENTIVE PERFORMANCE MATERIALS GMBH (DE) 2022-07-21 WO claimed
EP-3112352-A1 OPIOID RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2017-01-04 EP claimed
US-8088797-B2 Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US claimed
EP-1725537-B1 NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-07-13 EP claimed
US-20100041709-A1 SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-02-18 US claimed
US-20090171046-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2009-07-02 US claimed
EP-2075267-A2 Process for producing polydienes Bridgestone Corporation (JP) 2009-07-01 EP claimed
US-4533766-A Process for the production of dihydroxybenzenes DEGUSSA AKTIENGESELLSCHAFT (DE) 1985-08-06 US claimed
US-4029690-A WITH 2,5-DIMETHYL-2,4-HEXADIENE AND AN ALKYL DIAZOACETATE WITH A COPPER COMPLEX CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-06-14 US claimed
US-4029683-A WITH A SCHIFF BASE, CHRYSANTHEMATE SYNTHESIS CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-06-14 US claimed
US-20260124192-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS MODEL MEDICINES INC (US) 2026-05-07 US disclosed
US-RE50030-E1 Methods to treat lymphoplasmacytic lymphoma DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 US disclosed
WO-2024115641-A1 NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS UNIVERSITY OF COPENHAGEN (DK) 2024-06-06 WO disclosed
EP-0012240-A2 Process for manufacturing of optionally substituted benzaldehyd-dialkyl acetals BAYER AG (DE) 1980-06-25 EP disclosed
US-4174460-A Process for the hydroxylation of phenols and phenol ethers in the nucleus BAYER AKTIENGESELLSCHAFT (DE) 1979-11-13 US disclosed
US-4113782-A CATALYTIC OXIDATION AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1978-09-12 US disclosed
US-4045496-A Process for the hydroxylation of phenols and phenol ethers in the nucleus BAYER AKTIENGESELLSCHAFT (DT) 1977-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124192-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS SARS1, NSUN2, NSUN3 ALDH1A3 2622/4885KMT2A 1708/4885MAPT 153/4885
US-20100041709-A1 SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF PRMT3, PRMT5, PRMT1 ALDH1A3 1467/4885KMT2A 1197/4885MAPT 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.